GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the first quarter ended March 31, 2016. RECENT HIGHLIGHTS & ACCOMPLISHMENTS: Initiated the multi-center PRECISE II pivotal clinical trial in the United States to demonstrate safety and effectiveness of the
For more information, please visit
http://www.businesswire.com/news/home/20[...]Quarter-2016-Financial-Results